Details

Autor(en) / Beteiligte

• Yamada, Tadaaki
• Hirai, Soichi
• Katayama, Yuki
• Yoshimura, Akihiro
• Shiotsu, Shinsuke
• Watanabe, Satoshi
• Kikuchi, Toshiaki
• Hirose, Kazuki
• Kubota, Yutaka
• Chihara, Yusuke
• Harada, Taishi
• Tanimura, Keiko
• Takeda, Takayuki
• Tamiya, Nobuyo
• Kaneko, Yoshiko
• Uchino, Junji
• Takayama, Koichi

Titel

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer

Ist Teil von

• Cancer medicine (Malden, MA), 2019-04, Vol.8 (4), p.1521-1529

Ort / Verlag

United States: John Wiley & Sons, Inc

Erscheinungsjahr

2019

Quelle

Wiley Online Library - AutoHoldings Journals

Beschreibungen/Notizen

• Background Treatment with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) leads to initial response in most patients with EGFR‐mutated non‐small cell lung cancer (NSCLC). In contrast, little is known of the subpopulation of patients with NSCLC with EGFR mutations who exhibit clinical outcomes that require treatment with immune checkpoint inhibitors (ICIs). Therefore, to identify eligible cases to treat with ICIs, we retrospectively analyzed the correlation between clinical features and the efficacy of ICIs in patients with EGFR mutations. Patients and Methods We retrospectively analyzed patients with advanced NSCLC harboring EGFR mutations who were treated with ICIs after developing resistance to EGFR‐TKIs between February 2016 and April 2018 at 6 institutions in Japan. The association between clinical outcomes and the efficacy of ICIs was investigated. Results We enrolled 27 patients who harbored EGFR‐activating mutations. The objective response and disease control rates were higher in patients with uncommon EGFR mutations than in those with common EGFR mutations (71% vs 35.7% and 57% vs 7%, P = 0.14 and P < 0.01, respectively). Patients with uncommon EGFR mutations or without T790M mutations exhibited a significantly longer median progression‐free survival than those with common EGFR mutations or with T790M mutations (P = 0.003 and P = 0.03, respectively). Conclusion Patients with uncommon EGFR mutations and without T790M mutations are associated with the best outcomes for treatment with immunotherapy among those with EGFR‐mutated NSCLC, based on retrospective analysis. Further research is needed to validate the clinical biomarkers involved in ICI responders with EGFR mutations. It remains unclear EGFR‐mutated patients who have clinical outcomes of Immune checkpoint inhibitors (ICIs). In this study, we revealed the clinical factor of ICI responders among EGFR‐mutated NSCLC. Uncommon mutation and without T790M mutation are associated to ICI efficacy.